Hematology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haspel, R. L.
Right arrow Articles by Hillmen, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haspel, R. L.
Right arrow Articles by Hillmen, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hematology 2008

Which Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Should Be Treated with Eculizumab?

ASH Evidence-based Review 2008

Richard L. Haspel1 and Peter Hillmen2

Correspondence: Richard L. Haspel, MD, Beth Israel Deaconess Medical Center, Department of Pathology, 330 Brookline Avenue, Yamins 309, Boston, MA 02215; Phone 617-667-4344; Fax 617-667-7120; e-mail haspelr{at}yahoo.com

Abstract

A 45-year-old woman presents for evaluation as a result of persistent anemia. Ultimately, she is diagnosed with hemolytic anemia ascribed to paroxysmal nocturnal hemoglobinuria. She is otherwise well and has an otherwise normal complete blood cell count. She requires transfusion about once every 6 weeks for symptomatic anemia. She wonders whether she would benefit from eculizumab.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society of Hematology.